|
Agent and formulation |
Dosing | ||
|
Usual |
Maximum | ||
|
Acemetacin | |||
|
Capsules |
60 mg bid to tid |
600 mg/d | |
|
Sustained-release capsules |
90 mg once daily or bid |
300 mg/d | |
|
Celecoxiba: capsules |
200 mg once daily or 100 mg bid |
200 mg bid | |
|
Dexibuprofen: coated tablets |
200-400 mg tid |
1.2 g/d | |
|
Dexketoprofen | |||
|
Coated tablets |
25 mg tid |
75 mg/d | |
|
PO granulate for suspension |
25 mg tid |
75 mg/d | |
|
Solution for IV/IM injections |
50 mg every 8-12 hours |
150 mg/d | |
|
Diclofenaca | |||
|
Tablets, capsules |
50 mg every 8-12 hours |
100 mg/d | |
|
Sustained-release tablets Modified-release tablets Sustained-release capsules Modified-release capsules |
50-100 mg once daily or in 2 divided doses |
100 mg/d | |
|
Suppositories, rectal capsules |
50-100 mg/d in 2-3 divided doses |
100 mg/d | |
|
Solution for IM injections |
75 mg once daily |
75 mg bid | |
|
Topical spray, gel, patch |
Topically several times a day |
| |
|
Etofenamate: topical gel, cream, spray |
Topically several times a day |
| |
|
Ibuprofena | |||
|
Various PO formulations |
Rheumatic diseases 400-800 mg tid to qid, analgesic treatment 200-400 mg 4-6 times/d |
3.2 g/d | |
|
Cream, gel |
Topically |
| |
|
Indomethacina | |||
|
Immediate-release |
25-50 mg bid or tid |
200 mg/d | |
|
Sustained-release tablets |
75 mg once daily or bid |
75 mg bid | |
|
Spray, ointment |
Topically several times a day |
| |
|
Ketoprofena,b | |||
|
Tablets |
100 mg once daily or bid |
300 mg/d | |
|
Capsules |
50 mg tid |
300 mg/d | |
|
Modified-release tablets |
150 mg once daily or in 2 divided doses |
150 mg bid | |
|
Sustained-release tablets Sustained-release capsules |
100-200 mg once daily |
200 mg once daily | |
|
Suppositories |
100 mg once daily or bid |
300 mg/d | |
|
Gel |
Topically bid |
| |
|
Topical spray |
3-4 doses once daily to tid |
48 doses in 24 hours | |
|
Solution for IM injections |
100 mg once daily to bid |
200 mg/d | |
|
Mefenamic acid | |||
|
Tablets |
250 mg qid |
| |
|
Suppositories |
500 mg once daily to tid |
500 mg qid | |
|
Tiaprofenic acid: tablets |
300 mg bid |
| |
|
Tolfenamic acid: tablets |
200 mg |
400 mg | |
|
Meloxicama | |||
|
Tablets |
7.5-15 mg once daily |
15 mg once daily | |
|
Suppositories |
7.5-15 mg once daily |
15 mg once daily | |
|
Solution for IM injections |
15 mg once daily |
15 mg once daily | |
|
Nabumetone: tablets |
1-2 g once daily or 0.5-1 g bid |
2 g/d | |
|
Naproxena | |||
|
Tablets, PO suspension |
250-500 mg bid |
1.5 g/d | |
|
Suppositories |
250-500 mg bid |
1.5 g/d | |
|
Gel |
Topically 2-6 times/d |
| |
|
Nimesulidec: tablets, granulate for PO suspension |
100 mg bid |
| |
|
Piroxicamd: tablets, solution for IM injections |
20 mg once daily or 10 mg bid |
40 mg/d | |
|
Diethylamine salicylate: cream, gel |
Topically tid or qid |
| |
|
a Agents commonly used in Canada. b One of the chapter’s contributors preferred to specify ketoprofen should be used at the maximum dose only for up to several days. c Not indicated in osteoarthritis; due to the risk of liver injury it should be used as a second-line agent at the lowest effective doses and for the shortest time possible (up to 15 days). d One of the chapter’s contributors preferred to remove piroxicam as an option due to its adverse effect profile. | |||
|
bid, 2 times a day; IM, intramuscular; IV, intravenous; PO, oral; qid, 4 times a day; tid, 3 times a day. | |||